Economic Hotspot Quick Review | Ensuring Quality and Supply Is the Lifeline of Centralized Procurement Drugs

Ask AI · How do centralized procurement pharmaceutical companies ensure drug quality and supply stability?

Recently, the National Medical Insurance Drug Procurement Office announced the list of suppliers involved in centralized procurement who failed quality inspections or could not guarantee supply. Several companies, including Guangzhou Hehe Pharmaceutical and Beijing Fukan Ren Biological Pharmaceutical, were disqualified from winning bids and listed as violations. The relevant penalties were swiftly implemented, drawing public attention. This incident is not only a stern warning to a few dishonest and irresponsible pharmaceutical companies but also a reminder: maintaining quality and supply is the bottom line that cannot be touched in centralized procurement, and it is crucial for people’s well-being and the survival of enterprises.

Bulk drug procurement is a major livelihood project benefiting hundreds of millions of people. By exchanging volume for price, it allows the public to access high-quality, affordable generic medicines, effectively reducing their medical and drug expenses. This responsibility carries the hope of health for millions of patients and imposes a heavy burden on winning companies in the procurement process. However, despite strict rules and rigorous supervision, some companies violate their integrity commitments—either by poor production management leading to serious drug defects or by ignoring supply agreements, failing to provide timely and sufficient supplies, disrupting clinical medication orderliness, and directly harming patients’ interests.

This image appears to be AI-generated.

Such behaviors—ignoring drug quality and betraying supply commitments—are irresponsible to public health and show a disregard for the seriousness of the drug procurement system. They should be strongly condemned and severely punished. The pharmaceutical industry is a special field dedicated to saving lives and cannot tolerate opportunism. If companies abandon their conscience and bottom line, even if they temporarily gain market share, they will ultimately be rejected by the market.

Since the establishment of the drug procurement system, the National Healthcare Security Administration and related departments have maintained a “zero tolerance” policy toward quality issues of winning drugs: strengthening quality supervision throughout the entire lifecycle of selected products, establishing a risk management mechanism for product quality, and implementing joint sanctions on products with quality risks. The swift response and serious accountability in this case fully demonstrate the determination of relevant departments to ensure drug safety for the public and create a fair competitive environment for honest and compliant enterprises. This sends a clear message to society: centralized procurement is not a battlefield for price competition but a platform for quality and responsibility.

The quality and supply of drugs in centralized procurement are not only the lifelines of the procurement system but also the lifelines of every participating enterprise. “If you don’t have a diamond drill, don’t take on porcelain work.” To achieve steady and long-term development, companies must demonstrate strength and responsibility. Only by strictly aligning with national standards, meticulously controlling processes, and ensuring stable production capacity according to commitments can they stand firm in the procurement competition.

(Source: People’s Daily Client )